Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives $40.80 Average Price Target from Analysts

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the company, reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $40.80.

Several analysts recently issued reports on CALT shares. HC Wainwright assumed coverage on Calliditas Therapeutics AB (publ) in a report on Friday, February 26th. They set a “buy” rating and a $52.00 price objective for the company. Zacks Investment Research raised shares of Calliditas Therapeutics AB (publ) from a “sell” rating to a “hold” rating in a research report on Tuesday, May 11th.

Shares of NASDAQ:CALT traded up $1.33 during midday trading on Friday, hitting $31.01. 110 shares of the stock were exchanged, compared to its average volume of 34,796. Calliditas Therapeutics AB has a 52-week low of $19.00 and a 52-week high of $38.00. The stock’s fifty day moving average is $28.43. The company has a market cap of $774.35 million and a P/E ratio of -13.37.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings data on Monday, May 17th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.17). Sell-side analysts predict that Calliditas Therapeutics AB will post -2.74 EPS for the current fiscal year.

Several large investors have recently modified their holdings of CALT. Hillhouse Capital Advisors LTD. grew its position in shares of Calliditas Therapeutics AB (publ) by 199.3% in the fourth quarter. Hillhouse Capital Advisors LTD. now owns 1,047,687 shares of the company’s stock valued at $35,611,000 after purchasing an additional 697,687 shares during the last quarter. Endurant Capital Management LP acquired a new stake in shares of Calliditas Therapeutics AB (publ) in the first quarter valued at about $3,923,000. Citadel Advisors LLC acquired a new stake in shares of Calliditas Therapeutics AB (publ) in the first quarter valued at about $264,000. Finally, Tudor Investment Corp Et Al acquired a new stake in shares of Calliditas Therapeutics AB (publ) in the first quarter valued at about $380,000. 9.35% of the stock is currently owned by institutional investors.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.

Further Reading: Cost of Debt

Analyst Recommendations for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with's FREE daily email newsletter.